Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT
Standard
Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. / Styczynski, Jan; Tridello, Gloria; Gil, Lidia; Ljungman, Per; Mikulska, Malgorzata; Ward, Katherine N; Cordonnier, Catherine; de la Camara, Rafael; Averbuch, Diana; Knelange, Nina; Socié, Gerard; Chevallier, Patrice; Blaise, Didier; Yakoub-Agha, Ibrahim; Forcade, Edouard; Cornelissen, Jan; Maertens, Johan; Petersen, Eefke; Nguyen-Quoc, Stéphanie; Veelken, Hendrik; Schaap, Nicolaas; Passweg, Jakob; Michallet, Mauricette; Fegueux, Nathalie; Deconinck, Eric; Russell, Nigel; Basak, Grzegorz; Bader, Peter; Montoto, Silvia; Kröger, Nicolaus; Cesaro, Simone; Infectious Diseases Working Party EBMT.
in: BONE MARROW TRANSPL, Jahrgang 54, Nr. 12, 12.2019, S. 2060-2071.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT
AU - Styczynski, Jan
AU - Tridello, Gloria
AU - Gil, Lidia
AU - Ljungman, Per
AU - Mikulska, Malgorzata
AU - Ward, Katherine N
AU - Cordonnier, Catherine
AU - de la Camara, Rafael
AU - Averbuch, Diana
AU - Knelange, Nina
AU - Socié, Gerard
AU - Chevallier, Patrice
AU - Blaise, Didier
AU - Yakoub-Agha, Ibrahim
AU - Forcade, Edouard
AU - Cornelissen, Jan
AU - Maertens, Johan
AU - Petersen, Eefke
AU - Nguyen-Quoc, Stéphanie
AU - Veelken, Hendrik
AU - Schaap, Nicolaas
AU - Passweg, Jakob
AU - Michallet, Mauricette
AU - Fegueux, Nathalie
AU - Deconinck, Eric
AU - Russell, Nigel
AU - Basak, Grzegorz
AU - Bader, Peter
AU - Montoto, Silvia
AU - Kröger, Nicolaus
AU - Cesaro, Simone
AU - Infectious Diseases Working Party EBMT
PY - 2019/12
Y1 - 2019/12
N2 - The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997-2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D- (HR = 1.21; p = 0.044), and R-/D + (HR = 1.21; p = 0.048) in comparison to R-/D- transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R-/D-): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-negative donor in context of chronic GVHD, while there are no preferences in donor EBV serostatus for EBV-seropositive recipient.
AB - The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997-2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D- (HR = 1.21; p = 0.044), and R-/D + (HR = 1.21; p = 0.048) in comparison to R-/D- transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R-/D-): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-negative donor in context of chronic GVHD, while there are no preferences in donor EBV serostatus for EBV-seropositive recipient.
U2 - 10.1038/s41409-019-0627-9
DO - 10.1038/s41409-019-0627-9
M3 - SCORING: Journal article
C2 - 31363166
VL - 54
SP - 2060
EP - 2071
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 12
ER -